A a S T R A C T Studies were undertaken to determine whether deoxyribonuclease I, (DNase I) once immobilized on activated nylon microspheres, would be capable of degrading circulating DNA in vitro and in vivo in an extracorporeal circulation system in dogs. Nylon microspheres were prepared and after gentle hydrolysis and glutaraldehyde treatment, demonstrated a retention of up to 4.73 mg of Dnase I. In vitro studies showed that DNase I immobilized on microspheres degraded a significant percentage of 'I-native DNA (nDNA) within 15 min. Mongrel dogs were injected with^I -nDNA and a variation in initial tj in individual animals was observed. Therefore, for experimental studies, 'I-nDNA was injected and decay was recorded during a control period in which untreated microcapsules were utilized in the extracorporeal system. DNase I microspheres were then introduced into the extracorporeal circuit which resulted in an acceleration of degradation of acid precipitable 'I-nDNA. When 200 Ag of unlabeled DNA with "I-nDNA was injected, a similar augmentation of DNA degradation was noted after extracorporeal circulation over DNase I microcapsules. This effect could not be attributed to release of DNase I from the microspheres since no mI-DNase was detected in the serum or organs of the dogs at the conclusion of the experiments.
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INTRODUCTION
The role of DNA: anti-DNA complexes in the pathogenesis of some cases of systemic lupus erythematosus (SLE)' has been suggested and there is now considerable evidence to support this possibility. DNA antibodies and DNA: anti-DNA complexes occur frequently in association with acute exacerbations of the disease and DNA has been shown occasionally in the sera of patients with acute lupus nephritis after disappearance of detectable anti-DNA (1) (2) (3) (4) . Further, DNA has been demonstrated along the glomerular basement membrane by fluorescent antibody technique and anti-DNA antibodies have been eluted from postmortem kidneys of patients with SLE (2, 3) .
Therapy for SLE has largely been reliant upon immunosuppressive drugs that nonspecifically depress host immunity leaving the patient vulnerable to a wide variety of infectious agents. Another therapeutic approach would appear to be the specific removal from the circulation of the immune substances that are pathogenic in the disease. Preliminary studies utilizing an immuno-'Abbreviations used in this paper: DNase I, or DNase, deoxyribonuclease I; nDNA, native DNA; SLE, systemic lupus erythematosus; TCA, trichloroacetic acid. adsorbent composed of DNA-cellulose entrapped in agarose showed the feasibility of specifically withdrawing DNA antibody from the circulation of actively immunized rabbits (5, 6) . The (15) . Preparation of microcapsules. Nylon microcapsules were prepared as follows: a solution containing 9.2 g of 1,6-hexanediamine, 1.6 g of NaH2CO3, and 6.6 g of Na2COs in 100 ml of distilled water was prepared. A second solution consisting of 50 ml of chloroform, 200 ml of cyclohexane, and 2 ml of sebacolyl chloride was prepared and placed in a 500-ml beaker. A Pasteur pipette was tapered with heat to an internal diameter between 0.1 and 0.05 mm. The diamine solution was rapidly added dropwise into the second solution and solid nylon capsules 1.0-1.1 mm in diameter were formed at the bottom of the beaker. The capsules in the solution were swirled to separate them and then poured through a 20 mesh screen to dry them and remove debris. The capsules were then enclosed between a 42-mesh standard testing sieve and a 170 mesh sieve and washed with 2,000 ml of distilled water. Capsules were collected and stored in distilled water at 40C.
Conjugation of DNase to microcapsules. Microcapsule chambers consisted of a glass cylinder 8 cm in length with an internal diameter of 2.5 cm with 40 mesh stainless steel screens at the ends (R. H. Allen Co., Boulder, Colorado). This chamber was filled with approximately 300 microcapsules 1.0-1.1 mm in diameter and then attached to a roller pump by polyethylene tubing. The capsules were washed with 2,000 ml of distilled water at 30°C and then gently hydrolyzed with 500 ml of 3 M HCl which was circulated at 30'C for 60 min at a flow rate of 30 ml/min. The capsules were washed with distilled water at 0C. Glutaraldehyde, 4%o wt/vol (Eastman Organic Chemicals Div., Rochester, N. Y.) in 0.1 M borate buffer pH 8.3 was circulated for 15 min at 0C and the capsules then washed with 0.1 M borate buffer pH 8.3 at 0C. The pump tubing was changed. DNase (15 mg) plus 'I DNase (1 jig) as a marker was circulated in 50 ml of 0.1 M phosphate buffer pH 7.05 containing 100 mg of MgCla at 0C for 1 h. Capsules were then washed with 500 ml of 0.1 M phosphate buffer pH 7.05 containing 1,000 mg of MgCl2 until the wash contained no 'I counts per minute above background. The capsules were warmed to room temperature, and transferred in solution to a siliconized chamber for in vivo use.
In vivo extracorporeal system. Dogs were anesthetized with sodium pentabarbital and the femoral artery and vein cannulated with wide bore polyethylene tubing. Sodium heparin, 3 mg/kg, was inj ected intravenously and the femoral artery and venous catheters were connected to a Travenol hemodialysis pump (Travenol Laboratories, Deerfield, Ill.) and then to the microcapsule chamber. The latter had been coated with silicone (Clay Adams, Parsippany, N. J.) just before use. A three-way stop clock assembly made it possible to reverse the flow of blood through the chamber at 7-12-min intervals to prevent the microcapsules from impeding flow by clogging the screens. The chamber was connected to a bubble trap and then to the femoral vein. Heparinized blood was circulated through the extracorporeal system for 20 min before injection of DNA. Flow rate was sustained at 200 ml/min during the entire procedure. Samples of blood were withdrawn from the venous line and sampled for 'I-nDNA and degradation products at various intervals. Schematic representation of this system is shown in Fig. 1 .
Measurement of acid precipitable DNA. This was performed by adding 0.2 ml of dog serum to 1 ml of cold 0.1 M phosphate buffer pH 7.05. To this solution, 10% trichloroacetic acid (TCA) (1 ml) at 40C was added. After centrifugation at 2,000 rpm for 15 min at 40C, the supernate was removed with a Pasteur pipette. The portions of antisera to nDNA obtained from a patient with SLE. The mixture was incubated at 4VC for 72 h and then centrifuged at 2,000 rpm for 30 min at 4VC. The precipitates were washed three times in cold phosphate buffered saline pH 7.0 and redissolved in 0.05 ml of 0.1 N NaOH. The protein content was measured using the Lowry et al. method (16) , with the OD read at 720-mu in a Beckman 25 spectrophotometer. The quantitative precipitin curve was plotted and the point in antigen excess at which no spontaneous precipitation occurred was determined. For the serum used, this point was at 62 ,ug of DNA/ml serum.
Soluble DNA: anti-DNA complexes were prepared by incubating 62 4ug of 'I-nDNA with 1 ml of the same antiserum for 72 h at 40 C. The mixture was centrifuged at 2,000 rpm at 4VC for 30 min, the supernate was decanted, and an equal volume of saturated (NH4),SO4 was added to it. The mixture was incubated and centrifuged for 30 min at 4VC. The supernate was discarded, the precipitate redissolved in phosphate buffered saline pH 7.0 and the process repeated until the precipitate contained more than 95% of the 'I-DNA present. The precipitate was redissolved in phosphate buffered saline pH 7.0 and dialyzed against phosphate buffered saline for 48 h. The final solution contained all the gamma globulin and also 10 sg of 'InDNA in the DNA: anti-DNA complexes.
Measurement of DNA: anti-DNA complexes in zivo. To 0.5 ml of serum was added 0.5 ml of saturated (NH)2SO4 plus 5 ml of 50%o saturated (NH4)2SO4. Hematologic studies. Leukocyte counts on dog blood were performed in the Coulter counter (Coulter Electronics Inc., Hialeah, Fla.). Hematocrits were determined by centrifugation of whole blood in capillary tubes. Platelet counts were performed in a Neubauer counting chamber (Neubauer Mfg. Co., Minneapolis, Minn.).
RESULTS
Retention of DNase on microcapsules. DNase (15 mg) was circulated through a chamber containing approximately 300 microcapsules and conjugated to the nylon as described in Methods. After use of the capsules for in vitro or in vivo experiments, they were removed from the chamber, washed with 300 ml of saline and counted in a Picker gamma scintillation counter. The quantity of DNase I retained was calculated by determining the percentage of the total 'I-DNase added which was bound to the capsules at the conclusion of the experiment. The results shown in Table I demonstrate that under the conditions described between 26.8 and 31.5% (4.02-4.73 mg) of DNase was retained on the microcapsules (Table I) .
Degradation of labeled nDNA by immobilized DNase in vitro. Fresh normal dog blood (100 ml) was drawn from the femoral artery to which 300 U of sodium heparin was added. 'I-nDNA, 3.0 X 10' cpm (2 sug) plus MgCI6 (100 mg) was added to the blood. The It may be seen that the decay rate for these substances varied from animal to animal (Fig. 3) . Because of the variation in individual decay rates for these substances, it was necessary for each animal to serve as his own control in experimental studies. Accordingly, in order to determine the effect of DNase microcapsules on nDNA degradation in experimental dogs, a control decay period was first carried out in each dog. The decay rate of nDNA after introduction of DNase microcapsules in each dog was then compared with its own control decay curve and statistical analysis performed on the control and experimental slopes.
In experimental and control animals, the initial pattern of decay of nDNA and nDNA: anti-DNA complexes was linear and curvilinear, respectively. In all the control animals, degradation lines were curvilinear when they were carried out to a point where 15%
of the original counts were remaining in the serum of each animal. Therefore, in each experimental animal, the control portion of the slope (untreated microcapsules) was 5a and 5b, respectively. Dogs in Figs. 5c and 5d which received the MgCla infusion showed increases of 92 and 739%, respectively. Degradation of nDNA in nDNA: anti-DNA complexes in vitro. Soluble nDNA: anti-DNA complexes were prepared as described in Methods. Fresh normal dog blood (100 ml) was drawn from the femoral artery and 300 U of sodium heparin added. nDNA: anti-DNA complexes in antigen excess containing 2 *g of 1I-nDNA was added with MgCla (100 mg). The blood was incubated for 15 min at 27°C and then drawn into polyethylene tubing and circulated by a roller pump at 200 ml/min through a chamber containing DNase microcapsules. Results showed a marked increase in the percentage of (NH4)2S04 soluble 1"I-nDNA 15 min after circulation of immune complexes over DNase microcapsules (Fig. 6) .
Degradation of nDNA in nDNA: anti-DNA complexes in vivo (group III). Soluble nDNA: anti-DNA complexes were prepared as described in Methods. Two dogs were injected with I25J-nDNA: anti-DNA (106 cpm) containing 2 ,ug of 'I-nDNA. A slow infusion of 10% MgCh (total infusion volume, 0.5-1.0 ml) was continued for the course of each procedure. After an equilibration period of 2 min, untreated microspheres were inserted into the extracorporeal circulation for approximately 7 min. DNase microspheres were then placed in the circuit which resulted in a rapid decrease in the quantity of (NH4)2S04 precipitable "2I-nDNA (Figs. 7a and b) .
Release of DNase from the microcapsules. To determine whether the observed degradation of "25I-nDNA was due to DNase released from the microcapsules during the experiments, vital organs and serum of the dogs were counted for the presence of 131I at the conclusion of each experiment. Results showed no significant 'I in organs and serum of the dogs above background suggesting that the degradation of "2I-nDNA was effected by the immobilized enzyme and not due to enzyme released from the microcapsules (Table II) . Hematologic studies on dogs undergoing extracorporeal circulation. Studies of hematocrit, leukocyte, and platelet counts were performed on dogs before and after extracorporeal circulation across the DNase micro- capsules. Results showed no appreciable alteration in hematocrits or platelet counts during the procedure (Table III) . There was, however, a reduction in leukocyte counts in all animals studied. In four animals, the decline was moderate (postperfusion values not more than 2,000/mm8 below preperfusion figures). In three animals, there were significant reductions in the postperfusion leukocyte counts. However, examination of the capsules at the conclusion of each experiment revealed no evidence of thrombotic material or significant residual cellular debris on their surface.
DISCUSSION
These foregoing studies demonstrate that nylon microcapsules which have been subjected to mild hydrolysis and glutaraldehyde treatment will bind significant quantities of DNase. Once immobilized on the nylon microcapsules, the DNase appears to retain sufficient function to accelerate the degradation of nDNA circulating free or as nDNA: anti-DNA complexes in vitro and in vivo in dogs. The observed effect of DNase on nDNA degradation could, in all likelihood, be attributed to the enzyme which was covalently conjugated to the nylon microcapsules since (a) no significant free mI-DNase could be detected in the tissues or serum of experimental animals at the conclusion of the experiments, NO MICROCAPSULES (b) there was no significant uptake of 'I recovered in the thyroid gland at the conclusion of the experiments, (c) no significant 'I-DNase was identified in a serum sample taken at the conclusion of the in vitro nDNA degradation study.
Previous studies have established the linear or curvilinear decay pattern of DNA after it was injected into experimental animals (17) . A variation in the timecourse of decay was observed depending on the quantity of DNA that was administered (17) . The present study shows considerable variation in the initial tj of nDNA decay in mongrel dogs (Fig. 3) which may be attributed, in part, to individual differences in compartmentalization, as well as the quantities of circulating nucleases and inhibitors (18) (19) (20) . In view of these findings, to demonstrate the effect of immobilized DNase in degrading circulating nDNA in vivo, it was necessary for each animal to serve as his own control. Therefore, after injection of nDNA into experimental dogs, a phase of normal nDNA degradation lasting from 4 to 10 min was plotted. While the initial tj rate for this phase varied from animal to animal (Fig. 3) , a linear degradation pattern was discernable in control and experimental animals during this period. At the end of this phase, DNase microcapsules were introduced into the extracorporeal circuits, which resulted in statistically 10,000 9,000 8,000 7,000 6,000 5,000- Each of three dogs was infused with 17 ,ug of 'I-nDNA. In the three animals studied, there was an abrupt increase in the rate of 'I-nDNA degradation after introduction of DNase I microcapsules into the extracorporeal circuit (uninterrupted lines). Regression analysis of dogs depicted in Fig. 4a shows the change in slope at 15 min to be significant (P < 0.003). Fig. 4b , regression lines to points taken up to 8 min and to those between 12 and 27 min reveal a difference (P <<0.001) indicating that the decline at 8 min is significant. In Fig. 4c , the data points after the introduction of DNase I microcapsules fall 22, 15, 13, and 9 SD below their predicted values. The probability of this occurring is P <<0.01, thus the drop at 15 min is significant. Interrupted lines represent extrapolations of each animal's control decay curve into the experimental period for comparative purposes.
significant changes in the slopes of nDNA degradation compared to their own initial and extrapolated control slopes in each experimental animal studied.
A reduction in postperfusion leukocyte counts was observed in all animals studied without associated alterations in hematocrits or platelet counts. This decline in leukocyte counts was probably not due to binding of leukocytes to the immunoadsorbent surface since (a) no significant cellular debris or thrombotic material was observed on the microcapsules and (b) there were no significant alterations of platelet counts, even though platelets have been observed to decline in some extracorporeal systems due to excessive adhesion to polymeric surfaces (21) . The explanation of the postperfusion decline in leukocyte counts is unclear at present. However, a reduction in leukocyte counts has been noted in patients undergoing extracorporeal hemodialysis (22) . This effect has been attributed to sequestration of leukocytes in extravascular pulmonary pools (22) . This phenomenon appears to be transient since leukocyte counts have been observed to normalize shortly after discontinuation of extracorporeal circulation (22) .
The requirement of divalent cations for the structural integrity and functional activity of DNase has been well SO soluble 'I-nDNA was noted 15 min after 'I-nDNA:
anti-DNA complexes in normal dog blood were circulated over DNase I microcapsules.
quirement for extra magnesium to augment the activity of the immobilized enzyme, any excessive accumulation of the ion could be dialyzed out of the plasma at the venous end of the extracorporeal circuit. Nylon was chosen as a material for use as an in vivo immunoabsorbent because of its relative inertness and minimal host toxicity demonstrated in previous experiments (7, 8) . Microcapsules were utilized because of their enormous surface area with minimum extracorporeal volume requirements. Similar microspheres have been previously used in vivo to encapsulate various proteins (7, 8) . The latter systems depend to some extent on the diffusability of the membrane to permit entrance of circulating substrate. For our system where diffusion was unimportant, we added additional hexanediamine in the synthesis of the capsules to strengthen them in the face of hydrolytic treatment. During in vivo circulation, the capsules were quite mobile in their chamber. Reversal of flow in the chamber at 7-and 12-min intervals prevented clogging of the screens and facilitated blood flow. At the conclusion of the experiments, the capsules appeared quite intact structurally and were free of thrombotic material and cellular debris.
It would appear that nylon microcapsules possess many features of the optimal immunoadsorbent. These include (a) large surface area and minimal extracorporeal volume requirement, (b) capacity to bind large quantities of protein, (c) firm adherence of material bound to it without release into the host, and (d) minimal toxicity to the host's hematologic status. Thus, this material would seem to have considerable potential for application to treatment of disease in man.
It appears that the optimal approach to autoimmune disease would be to reinstitute immune unresponsiveness to the pathogenic antigen. While there are numerous methods for inducing experimental tolerance in the unprimed host, it is quite difficult to reinduce this state in an animal that is immunized (23) . Since the host with autoimmune disease is immunized, the usual modalities of experimental tolerance induction would be predictably ineffective. However, promising approaches to the specific reinstitution of partial or complete tolerance in ongoing disease processes have been described (24) (25) (26) .
The extracorporeal approach herein described involves an attempt to hydrolyze pathogenic circulating immune reactants. As such, it might be employed during the active phase of SLE to degrade nDNA: anti-DNA complexes or alternatively on a prophylactic basis to reduce circulating levels of nDNA. Employed in this way, the system would be used to sustain the disease in a clinically quiescent state without actually achieving a state of absolute unresponsiveness. A compromise of this nature is perhaps analogous to the prevention of symptomatic uremia with the use of intermittent hemodialysis.
Previous studies have shown the feasibility of withdrawing nDNA antibodies from the circulation of actively immunized rabbits with an immunoadsorbent composed of nDNA entrapped in agarose (5, 6) . The specific withdrawal of circulating bovine serum albumin and anti-bovine serum albumin was effected with two different immunoadsorbents (27, 28 ). An extracorporeal system capable of effecting specific degradation of circulating nDNA alone or complexed with antibody coupled with specific removal of nDNA antibody might prove very effective in removing actual or potential pathogenic substances from the circulation of patients with SLE.
